Abstract
Drugs used in the treatment of diseases including malignancy are known to cause various lung injuries, including interstitial pneumonitis. With increasing incidence of malignancies and advent of newer and newer chemotherapy and immunological treatments, it is prudent on the part of the pulmonologist to identify such complications at the earliest so that appropriate treatment can be initiated and reduce morbidity and mortality due to such causes. Herewith is presented a case of a patient with invasive ductal carcinoma of the breast who developed interstitial pneumonitis after 2 weeks of treatment with docetaxel and trastuzumab and was managed successfully.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Association of Pulmonologist of Tamil Nadu
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
